78 related articles for article (PubMed ID: 9817063)
41. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W
J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011
[TBL] [Abstract][Full Text] [Related]
42. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.
Lin NU; Seah DS; Gelman R; Desantis S; Mayer EL; Isakoff S; Dipiro P; Krop IE; Come SE; Weckstein D; Winer EP; Burstein HJ
Breast Cancer Res Treat; 2013 Jun; 139(2):403-10. PubMed ID: 23645007
[TBL] [Abstract][Full Text] [Related]
43. Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.
Onyenadum A; Gogas H; Markopoulos C; Bafaloukos D; Aravantinos G; Mantzourani M; Koutras A; Tzorakoelefterakis E; Xiros N; Makatsoris T; Fountzilas G; Kalofonos HP
J Chemother; 2007 Oct; 19(5):582-9. PubMed ID: 18073159
[TBL] [Abstract][Full Text] [Related]
44. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Estévez LG; Batista N; Sánchez-Rovira P; Velasco A; Provencio M; León A; Dómine M; Cruz J; Rodríguez M
Clin Breast Cancer; 2008 Apr; 8(2):149-54. PubMed ID: 18621611
[TBL] [Abstract][Full Text] [Related]
45. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
Delva R; Pienkowski T; Tubiana N; Vanhoefer U; Longerey B; Douville I
Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
[TBL] [Abstract][Full Text] [Related]
46. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer.
Perrone F; De Placido S; Carlomagno C; Nuzzo F; Ruggiero A; De Laurentiis M; Gridelli C; Pagliarulo C; Bianco AR
Tumori; 1993 Aug; 79(4):254-7. PubMed ID: 8249178
[TBL] [Abstract][Full Text] [Related]
48. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
Nolè F; Crivellari D; Mattioli R; Pinotti G; Foa P; Verri E; Fougeray R; Brandely M; Goldhirsch A
Cancer Chemother Pharmacol; 2009 Sep; 64(4):673-80. PubMed ID: 19184601
[TBL] [Abstract][Full Text] [Related]
49. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
[TBL] [Abstract][Full Text] [Related]
50. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.
Spielmann M; Dorval T; Turpin F; Antoine E; Jouve M; Maylevin F; Lacombe D; Rouesse J; Pouillart P; Tursz T
J Clin Oncol; 1994 Sep; 12(9):1764-70. PubMed ID: 8083698
[TBL] [Abstract][Full Text] [Related]
51. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
[TBL] [Abstract][Full Text] [Related]
52. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.
Fumoleau P; Cortés-Funes H; Taleb AB; Chan S; Campone M; Pouget JC; Tubiana-Hulin M; Slabber CF; Caroff-Paraïso I; Alberts AS; Ben Ayed F
Am J Clin Oncol; 2009 Aug; 32(4):375-80. PubMed ID: 19487917
[TBL] [Abstract][Full Text] [Related]
53. Mitomycin C and vinblastine in anthracycline-resistant metastatic breast cancer: a phase II study.
Kalofonos HP; Onyenadum A; Kosmas C; Koutras A; Petsas T; Efthimiou V; Koukouras D; Tzoracolefterakis E; Andrikopoulos P; Androulakis J
Tumori; 2001; 87(6):394-7. PubMed ID: 11989593
[TBL] [Abstract][Full Text] [Related]
54. Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.
Urruticoechea A; Archer CD; Assersohn LA; Gregory RK; Verrill M; Mendes R; Walsh G; Smith IE; Johnston SR
Br J Cancer; 2005 Feb; 92(3):475-9. PubMed ID: 15685237
[TBL] [Abstract][Full Text] [Related]
55. Hydroxyurea did not enhance the clinical response to vinblastine in patients with anthracycline-resistant metastatic breast cancer.
Huan SD; Yau JC; Tomiak E; Goel R; Cripps C; Gertler SZ; Prosser IA; Stewart DJ
Tumori; 1996; 82(6):576-8. PubMed ID: 9061067
[TBL] [Abstract][Full Text] [Related]
56. Mitomycin-C, vinblastine, and lonidamine as salvage treatment of advanced breast cancer. A pilot study.
Zaniboni A; Montini E; Simoncini E; Marpicati P; Arcangeli G; Meriggi F; Marini G
Am J Clin Oncol; 1990 Dec; 13(6):520-3. PubMed ID: 2122716
[TBL] [Abstract][Full Text] [Related]
57. Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patients.
Ospovat I; Siegelmann-Danieli N; Grenader T; Hubert A; Hamburger T; Peretz T
Tumori; 2009; 95(6):683-6. PubMed ID: 20210229
[TBL] [Abstract][Full Text] [Related]
58. Mitomycin C and vinblastine in advanced refractory breast cancer.
Brambilla C; Zambetti M; Ferrari L; Bonadonna G
Tumori; 1989 Apr; 75(2):141-4. PubMed ID: 2500762
[TBL] [Abstract][Full Text] [Related]
59. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy.
Pasterz RB; Buzdar AU; Hortobagyi GN; Blumenschein GR
Cancer; 1985 Nov; 56(10):2381-4. PubMed ID: 4042070
[TBL] [Abstract][Full Text] [Related]
60. A cost--utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer.
Li N; van Agthoven M; Willemse P; Uyl-de Groot C
Anticancer Drugs; 2001 Jul; 12(6):533-40. PubMed ID: 11460000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
